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Abstract  33 
There are numerous reports of the use of RNA-DNA oligonucleotides (chimeraplasts) to  34 
correct point mutations in vitro and in vivo, including the human apolipoprotein E gene.  35 
Despite the absence of selection for targeting, high efficiency conversion has been reported.  36 
Although mainly used to revert deleterious mutations for gene therapy applications,  37 
successful use of this approach would have the potential to greatly facilitate the production of  38 
defined mutations in mice and other species. We have attempted to create a point mutation in  39 
the mouse apolipoprotein E gene by microinjection of chimeraplast into the pronuclei of 1- 40 
cell mouse eggs. Following transfer of microinjected eggs we analysed 139 E12.5 embryos,  41 
but obtained no evidence for successful conversion.   42 
  43 
Keywords:  gene targeting, pronuclear injection, chimeraplast, oligonucleotide,  44 
mutagenesis, SNP  45 
  46 
Introduction  47 
With the availability of the finished human genome sequence and the draft mouse genome  48 
sequence, the priority is now the analysis of gene function. Important goals are the  49 
determination of the phenotypes of animals that have deficiencies in every gene (Nadeau et  50 
al, 2001) and, at another level, determination of the functional significance of naturally  51 
occurring DNA sequence variation, most of which is in the form of single nucleotide  52 
polymorphisms. For these ambitions to be realised, the efficiency of the generation and  53 
analysis of mutants is critical. Mice are the pre-eminent system for experimental mammalian  54 
genetics, and various strategies are in place for high-throughput mutagenesis of mice  55 
(Zambrowicz et al, 1998; Chen et al, 2000; Munroe et al, 2000; Hrabe de Angelis, 2000;  56 
Nolan et al, 2000; Wiles et al, 2000).  These approaches are very powerful but they all have  57 
drawbacks: not least, they are all based on random events and there is no possibility of  58 
designing the mutation. Conventional gene targeting in ES cells is directed, permitting  59 
precisely designed mutations to be made in mice. Various refinements have streamlined the  60 
creation of mutants by gene targeting (Eggan et al, 2002; Seibler et al, 2003; Valenzuela et al,  61 
2003), but nevertheless, the process is technically demanding and remains relatively  62 
inefficient.  The ideal approach to complement these established techniques would be highly  63 
efficient directed mutagenesis of embryos, applicable not only to mice, but also to other  64 
species.  65 Tagalakis et al. 
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A number of laboratories have reported success in correcting single base mutations in a  66 
variety of target genes using synthetic oligonucleotides (e.g. Alexeev et al., 1998, 2000;  67 
Bandyopadhyay et al., 1999; Cole-Strauss et al.,1996; Kren et al., 1997, 1998, 1999;  68 
Tagalakis et al., 2001). These studies have been undertaken with the ultimate goal of gene  69 
therapy applications, and typically the mutations targeted were reversion mutations. In most  70 
of these studies, the effective reagents used were synthetic self-complementary  71 
oligonucleotides known as RNA-DNA oligonucleotides (RDOs) or chimeraplasts, that are  72 
composed of DNA and 2’-O-methyl RNA segments, and which have terminal hairpins and a  73 
GC clamp to aid stability. Such synthetic oligonucleotide reagents have been found to be  74 
capable of targeting specific mutations in a variety of systems, including a variety of  75 
mammalian cells in vitro; liver, muscle and melanocytes in vivo as well as plants, and yeast.  76 
We have used chimeraplasts to target changes to human apolipoprotein E (Tagalakis et al,  77 
2001). In cultured cells, we have converted (at best) over 50% of gene copies and have  78 
rigorously validated these conversions showing that they are specific, stable, heritable and  79 
functional.  80 
Successful use of synthetic oligonucleotides to target mutations directly in mouse embryos  81 
would dramatically speed up the production of specific mutant strains of mice because it  82 
would remove the need to build targeting vectors, ES cell culture and much else. For these  83 
reasons we have tested whether gene targeting can be accomplished in mouse embryos by  84 
microinjection of a chimeraplast.   85 
  86 
Materials and Methods  87 
Pronuclear microinjection  88 
Microinjection was done using standard procedures (Hogan et al, 1994). C57BL/6 x CBA/Ca  89 
F1 mice were used throughout, apart from CD1 vasectomised males. Females were  90 
superovulated with 5IU PMS and 5IU hCG; embryos were recovered in M2 medium and  91 
cultured in M16 in 5% CO2, under oil. The chimeraplast was dissolved in 10mM Tris-HCl  92 
pH8.0, 0.1mM EDTA. One pronucleus of each embryo was microinjected, and any embryo in  93 
which the injected pronucleus was not observed to swell was discarded. Following  94 
microinjection the embryos were cultured overnight. For assessment of chimeraplast toxicity,  95 
2-cell embryos were transferred to fresh M16 and cultured for a further three days, at which  96 
time they were evaluated. Normal blastocysts were those which had not fragmented, which  97 
had a single discrete blastocoel and which had expanded to at least fill the zona pellucida. To  98 
test for chimeraplast-mediated mutagenesis, 2-cell embryos were transferred (average 28 per  99 Tagalakis et al. 
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mouse, range 18-35); they were transferred to one oviduct of pseudopregnant foster mothers  100 
under avertin anaesthesia (Papaioannou & Fox, 1993). These experiments were performed  101 
fully in compliance with current UK legislation.  102 
  103 
Screening for the mutation  104 
The region of the mouse ApoE gene that includes the two sites that are most polymorphic in  105 
man was amplified by PCR using primers ccgacatggaggatctacgc and gcgaccttgctccaccagag.  106 
PCR conditions were 75mM Tris-HCl (pH8.8 at 25ْC), 20mM (NH4)2SO4, 0.01% Tween 20,  107 
1.5mM MgCl2, 0.1mM dNTPs, 10% DMSO, 0.6µM each primer and 0.04u/µl Taq  108 
polymerase. Following an initial denaturation for 5 mins at 95ْC, 36 cycles of 94ْC, 62ْC and  109 
72ْC (40 sec each) were performed with a final extension of 8mins at 72ْC. We sequenced  110 
PCR products from this region of the ApoE gene from wild-type mice from our colony, and  111 
the sequences obtained corresponded to the published sequence.  112 
DNA was prepared from E12.5 embryos by digesting embryo fragments (whole tail) in 100µl  113 
of 50mM KCl, 10mM Tris-HCl pH8.3 at 25ْC 10µg/ml gelatine, 0.045% Igepal CA-630,  114 
0.045% Tween 20, 0.5mg/ml proteinase K at 55ْC overnight. 7µl of the crude lysate was used  115 
per 25µl PCR reaction after heat inactivation of the proteinase K. For digestion with HinP1I,  116 
7µl of unpurified PCR products were mixed with an equal volume of H2O and 1µl of HinP1I  117 
(10u/µl) was added. Following overnight digestion, the DNA was run on 20%  118 
polyacrylamide gels (Novex) in TBE and stained with SYBR green I.  119 
  120 
Results  121 
We selected apolipoprotein E (ApoE) as a test target for targeted mutation in mouse because  122 
we had previously achieved high level conversion of human ApoE genomic and cDNA  123 
targets in cultured cells and in transgenic mouse tissue (Tagalakis et al, 2001). The three  124 
common variants of human ApoE are ApoE2, ApoE3 and ApoE4. ApoE3 is the most  125 
frequent; the ApoE2 and ApoE4 alleles differ by virtue of single nucleotide polymorphisms  126 
that cause amino acid sequence changes. ApoE2 and ApoE4 are risk factors for  127 
atherosclerosis and Alzheimer’s disease, respectively. We designed a CÆT transition  128 
mutation that would simultaneously generate an RFLP and an R150C change in mouse ApoE  129 
protein (figure 1a), creating a SNP that is equivalent to the human ApoE2 SNP. A  130 
chimeraplast was synthesised to create this mutation (figure 1b) and was microinjected into  131 
the pronuclei of 1-cell mouse embryos.   132 Tagalakis et al. 
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For the production of transgenic mice, the volume of DNA injected into pronuclei is typically  133 
about 2x10
-9ml, and the optimum concentration of DNA is around 2µg/ml; injection of DNA  134 
at concentrations above this significantly reduces the frequency of development of mice to  135 
term (Brinster et al, 1985). For a typical transgene of 10kb, this corresponds to about 350  136 
molecules of the construct; the chimeraplast is 68nt long, so a 2x10
-9ml injection would  137 
contain about 10
5 molecules. Double stranded DNA ends are recognised as a sign of  138 
chromosome damage; depending on the cell type and extent of the damage, the response to  139 
such damage may be cell cycle arrest, or apoptosis. To test whether chimeraplasts are toxic to  140 
preimplantation embryos we titrated the concentration of chimeraplast injected into pronuclei  141 
(0, 0.25, 2.5 and 25µg/ml), and embryos that survived the immediate trauma of injection were  142 
cultured for 4 days. Development to normal blastocyst was significantly reduced for embryos  143 
injected with buffer or with chimeraplast, but there was no significant difference between the  144 
chimeraplast and buffer injected embryos (figure 2). This shows that the major deleterious  145 
effects of injection are independent of the injected DNA, and are probably due to physical  146 
damage. For subsequent experiments we injected the DNA at 2.5µg/ml.   147 
To test for mutagenic activity of the chimeraplast, we injected it into pronuclear mouse eggs,  148 
transferred them into oviducts of pseudopregnant foster mothers, and harvested embryos 12  149 
days after transfer. A total of 662 eggs were injected, 420 of which developed to 2-cells and  150 
were transferred. 139 embryos were recovered at E12.5; DNA was extracted from each  151 
embryo, amplified and digested with HinP1I (figure 1c). None of the embryos gave the  152 
diagnostic 68bp fragment, and in other respects the restriction patterns were exactly as  153 
predicted (e.g. figure 3).   154 
  155 
Discusssion  156 
All of the vasectomised males used to generate the recipients were confirmed to be sterile by  157 
test matings, some of the embryo recipients were carrying very large numbers of foetuses (up  158 
to 17), and some recipients were not pregnant. In mice, embryos do not move from one  159 
uterine horn to the other. The embryo transfers were unilateral, and every foetus recovered  160 
was in the ipsilateral uterine horn; there was no sign of implantation in the contralateral  161 
uterine horns. For these reasons we are confident that all of the recovered foetuses were  162 
derived from the eggs that had been injected and transferred, and were not from accidental  163 
fertile matings.   164 Tagalakis et al. 
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Some recent publications (Albuquerque-Silva et al., 2001; van der Steege et al., 2001;  165 
Taubes, 2002) have highlighted the inconsistency of oligonucleotide-directed targeted  166 
mutation. Various possible reasons for this have been proposed, including inefficient delivery  167 
to the cell nucleus, degradation, toxicity, poor reagent quality and differential accessibility of  168 
different target genes. We circumvented many of these concerns: the ApoE gene was chosen  169 
because the human homologue has been successfully targeted; direct microinjection  170 
eliminates delivery problems as >10
5 molecules were injected per embryo; the chimeraplast  171 
gave a discrete band and showed no signs of degradation by gel electrophoresis (figure 4);  172 
and finally, the rate of development to blastocyst and to E12.5 of eggs microinjected with  173 
chimeraplast was incompatible with a toxicity effect.   174 
The reason for our failure to obtain targeted conversions is not clear. We believe that it is not  175 
feasible to inject much more chimeraplast DNA without incurring significant  176 
postimplantation embryo losses. It has been proposed that chimeraplast activity is dependent  177 
on mismatch repair mechanisms. It is possible that preimplantation embryos lack the  178 
necessary mismatch repair activity; e.g. 1- to 4-cell stage rat embryos appear not to express  179 
Msh2 mRNA (Harrouk et al, 2000), but on the other hand, they may contain Msh2 protein of  180 
maternal origin. If not, it may be possible to stimulate chimeraplast-mediated mutagenesis by  181 
coinjection of Msh2 protein or components that may be lacking. Alternatively the use of a  182 
different chemistry may promote conversions in preimplantation embryos. There have been  183 
reports of targeted mutagenesis mediated by various types of single-strand oligonucleotides  184 
in yeast and/or cultured mammalian cells, including oligonucleotides that contain a triplex- 185 
forming region (Culver et al, 1999), those protected with phosphorothioates (PTO) (e.g.  186 
Kenner et al, 2002; Lu et al, 2003), locked nucleic acids (LNA) (Parekh-Olmedo et al, 2002)  187 
or including peptide nucleic acids (PNA) either conjugated with DNA oligonucleotides or as  188 
an adjuvant (Rogers et al, 2002). The PTO and LNA modifications probably function to  189 
stabilise the oligonucleotides by preventing exonuclease digestion; the triplex-forming  190 
oligonucleotides and PNA are thought to improve targeting by enhancing the interactions  191 
between the oligonucleotide and their targets. As yet the efficiencies obtained with single- 192 
strand oligonucleotides have not been high, but a number of factors have been reported to  193 
influence the efficiency of conversion. These include which strand is targeted with respect to  194 
the direction of transcription (Liu et al, 2002a; Pierce et al,  2003), transcriptional activity of  195 
the target (Liu et al, 2002; Igoucheva et al, 2003; Brachman & Kmiec, 2004), replication  196 
status of the target (Brachman & Kmiec, 2004) and single strandedness of the targeting  197 
oligonucleotide (Radecke et al, in press). Treatments that have been reported to increase the  198 Tagalakis et al. 
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efficiency of conversion include treatment of the cells with DNA damaging agents (Ferrara &  199 
Kmiec, 2004; Ferrara et al, 2004), modification of histone acetylation (and thereby chromatin  200 
structure; Parekh-Olmedo et al, 2003) and expression of normal or modified recombination  201 
proteins (Lio et al, 2002b, 2004). Because of the great attractiveness of gene repair for gene  202 
therapy, work is likely to continue in this direction, at least for somatic cells, and it is possible  203 
that this will result in improvements. Should significant progress be made in this direction, it  204 
may be worthwhile revisiting the possibility of oligonucleotide-mediated mutagenesis in  205 
preimplantation embryos. In this context it is obvious that any modified treatment regime  206 
must be compatible with normal development to term, as well as efficient mutagenesis of  207 
most or all targets. A further important consideration for any targeted mutagenesis  208 
programme is that second site mutations caused by the treatment should be kept to a  209 
minimum. While it may be possible to breed out unlinked second site mutations, it is likely  210 
that treatments such as the deliberate induction of DNA damage would give rise to sufficient  211 
random mutations to confound the analysis of phenotype.  212 
  213 
Conclusions  214 
Whatever the reason for the apparent lack of chimeraplast mutagenic activity in mouse  215 
embryos, at present this technology is not suitable for large scale targeted mutagenesis  216 
programmes. Clearer understanding of the mechanisms of oligonucleotide-mediated targeted  217 
mutagenesis and the development of methods to increase the efficiency may, in the future,  218 
make this approach feasible.  219 
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Figure 1 
A                             T 
                           ↑ 
ATGCGGGATGCCGATGATCTGCAGAAGCGCCTAGCTGTGTACAAGGCA 
-M--R--D--A--D--D--L--Q--K--R--L--A--V--Y--K--A- 
                            ↓ 
                            C 
 
B        3’ 5’ 
       \/ 
 T CCGCCGATCTGCAGAAGTGCCTAGCTGTGT T 
T                                  T 
T                                  T 
 T GGCGGcuagacgucuTCACGgaucgacaca T  
 
C 
ccgacatggaggatctacgcaaccgactcgggcagtaccgcaacgaggtgcac
accatgctgggccagagcacagaggagatacgggcgcggctctccacacacct
gcgcaagatgcgcaagcgcttgatgcgggatgccgatgatctgcagaagcgcc
tagctgtgtacaaggcaggggcacgcgagggcgccgagcgcggtgtgagtgcc
atccgtgagcgcctggggcctctggtggagcaaggtcgc 
 
 
A:  Design of the mutation.    
The wild-type DNA and peptide sequence are shown. The target codon is shown in blue, and the 
targeted DNA sequence alteration is indicated in red; similarly the wild-type and mutant amino acids 
are shown. To test for successful mutation, we made use of the HinP1I restriction site (underlined) 
that overlaps the target codon; the wild-type sequence possesses a restriction site; the mutation was 
designed to destroy this site. 
B:  Structure of the chimeraplast.  The sequence that is homologous to the mouse 
ApoE target is shown in blue, with the bases mismatched with the target (and corresponding to the 
intended sequence change) shown in red; DNA residues are shown in UPPERCASE, 2’O-Me-RNA 
residues are shown in lowercase; the GC clamp and T residues of the hairpin loops are shown in 
black. 
C: PCR-RFLP  analysis.    
The complete sequence of the wild-type PCR product is shown, with the targets of the PCR primers 
underlined, HinP1I sites are double underlined, and the target nucleotide is shown in red. The 
diagnostic restriction site is flanked by sites 33bp upstream and 35bp downstream. The wild-type 
allele is predicted to give fragments of 87, 35, 33, 30, 24, 20, 9, 7 and 6bp in length; mutation would 
cause loss of the 35 and 33bp fragments and a new 68bp fragment.  
 Tagalakis et al. 
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Figure 2  Survival of embryos following injection of the chimeraplast. 
Pronuclear mouse embryos were injected with chimeraplast at 0.25, 2.5 or 25 ng/µl, or with buffer 
alone; the embryos were cultured overnight. The following day, the lysed embryos were discarded, 
and the remaining 2-cell embryos were transferred to fresh medium (only 1/294 embryos had failed to 
divide). Control uninjected 2-cell embryos were also transferred to fresh medium. Following a further 
3 days in culture, the normal blastocysts were counted. Chi-squared analysis shows that injections of 
buffer or 2.5µg/ml chimeraplast increased the frequency of abnormal development significantly 
(P<0.001;  χ
2=40.336, 1d.f. and P<0.001;  χ
2=53.811, 1d.f., respectively); the rates of normal 
development of chimeraplast-injected and control buffer-injected eggs were indistinguishable (for 
2.5µg/ml chimeraplast, P=0.361; χ
2=0.833, 1 d.f.) Tagalakis et al. 
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Figure 3  Representative screening results. 
ApoE PCR products from chimeraplast-injected embryos recovered at mid-gestation (E12.5) were 
digested with HinP1I to screen for the introduction of the CÆT mutation. Lanes 1-6 show 
representative patterns from such embryos. The mutant allele would give a new 68bp fragment (*), 
with the 35 and 33bp fragments being depleted. We obtained no evidence for successful mutation in 
any of the 139 embryos analysed. The lane labelled Con shows the pattern obtained from an untreated 
wild-type mouse; lane M contains molecular weight standards (Invitrogen 10bp ladder). 
87 
35 
33 
30 
20 
24 
*68 
Con M    1     2     3     4     5     6     7 Tagalakis et al. 
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Figure 4  Intactness of the chimeraplast. 
The chimeraplast was run on a 15% polyacrylamide gel and stained with ethidium bromide. The bulk 
of the material migrated in a discrete band; the higher molecular weight smear is typical of 
chimeraplasts and is probably caused by intermolecular base pairing. 